| __timestamp | BioCryst Pharmaceuticals, Inc. | MannKind Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 7461000 | 79383000 |
| Thursday, January 1, 2015 | 13047000 | 108402000 |
| Friday, January 1, 2016 | 11253000 | 46928000 |
| Sunday, January 1, 2017 | 13933000 | 74959000 |
| Monday, January 1, 2018 | 29514000 | 79716000 |
| Tuesday, January 1, 2019 | 37121000 | 74669000 |
| Wednesday, January 1, 2020 | 67929000 | 59040000 |
| Friday, January 1, 2021 | 118818000 | 77417000 |
| Saturday, January 1, 2022 | 159371000 | 91473000 |
| Sunday, January 1, 2023 | 213894000 | 94314000 |
Unlocking the unknown
In the competitive world of biotechnology, managing expenses is crucial for survival and growth. This chart provides a fascinating glimpse into the Selling, General, and Administrative (SG&A) expenses of MannKind Corporation and BioCryst Pharmaceuticals, Inc. from 2014 to 2023. Over this period, BioCryst Pharmaceuticals saw a staggering increase in SG&A expenses, growing by nearly 2800% from 2014 to 2023. In contrast, MannKind Corporation's expenses remained relatively stable, with a modest increase of about 19% over the same period. This divergence highlights the different strategic approaches of these companies. While BioCryst appears to be aggressively expanding its operations, MannKind seems to be maintaining a more conservative financial strategy. Understanding these trends can provide valuable insights for investors and industry analysts alike.
Who Optimizes SG&A Costs Better? Novo Nordisk A/S or MannKind Corporation
Pfizer Inc. or BioCryst Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Breaking Down SG&A Expenses: Gilead Sciences, Inc. vs BioCryst Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Neurocrine Biosciences, Inc. and BioCryst Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Viatris Inc. and MannKind Corporation
Who Optimizes SG&A Costs Better? Insmed Incorporated or BioCryst Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Halozyme Therapeutics, Inc. or MannKind Corporation
SG&A Efficiency Analysis: Comparing ADMA Biologics, Inc. and BioCryst Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Bausch Health Companies Inc. and BioCryst Pharmaceuticals, Inc.
Mesoblast Limited and BioCryst Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: MannKind Corporation vs Travere Therapeutics, Inc.
MannKind Corporation and Novavax, Inc.: SG&A Spending Patterns Compared